Design and discover novel drug candidates through advanced bioanalytical techniques for clinical and non-clinical research
The Drug Discovery Platform is one of the Centre for Translational Biology (CTB) Technology Platforms at the Research Institute of the McGill University Health Centre (RI-MUHC). Its fundamental objectives are to support discoveries of drug molecules and provide top-flight bioanalytical support to the scientific community. The platform is noted for expertise in multidisciplinary areas such as chemical synthesis and analytical chemistry using nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS).
The platform’s NMR capabilities open doors to metabolomics, lipidomics, foodomics, microbiology, as well as allergy, cancer and various other disease-related research areas. The expertise of platform staff allows handling of a wide range of investigator-initiated research challenges, and this translates into using the platform’s diversified set of instruments for multiple applications (e.g., solution and HR-MAS NMR, MALDI-TOF MS tissue analysis and liquid chromatography (LC) MS).
Applications and services
Bioanalytical technologies at the Drug Discovery Platform include:
- Chemistry laboratory
- Mass spectrometry (MS)
- MALDI-TOF MS imaging
- Nuclear magnetic resonance (NMR)
- Other analytical capabilities
Centre for Translational Biology Technology Platforms
The CTB Technology Platforms provide access to state-of-the-art technologies and instrumentation as well as top-level scientific expertise and training. Watch the video, explore the links below, and prepare to accelerate your research!